Pharmasyntez-Nord JSC successfully completed Good Manufacturing Practice certification in Brasilia. Since Pharmasyntez-Nord JSC is the first company in Russia to be authorized to produce finished formulations in this crucial South America region, this event is historic for the country’s pharmaceutical industry. A Certificate of GMP Compliance of a Manufacturer was issued by the Brazilian Health Regulatory Agency (ANSIVA).

GMP certification is an important aspect of ensuring the quality and safety of pharmaceuticals. Customers' and medical professionals' trust is bolstered by this certification, which guarantees that production processes adhere to strict international standards.

Nikita Punia, Executive Director of the Pharmasyntez Group of Companies, spoke about plans to increase collaboration in supplying medicines in the LATAM region:

“In the first quarter of 2025, Pharmasyntez-Nord JSC intends to begin the process of registering its medications in the Brazilian market. This is a move to strengthen our position in the Latin American market and to reaffirm our dedication to offering high quality medications”.